AbbVie: Tavapadon Meets Key Endpoints in Phase 3 Parkinson's Study
By Colin Kellaher
AbbVie on Thursday said a late-stage study of its recently acquired tavapadon drug candidate for the neurodegenerative disorder Parkinson's disease hit its key goals.
AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline versus placebo in adults with early Parkinson's.
The North Chicago, Ill., biopharmaceutical company said the study also met a key secondary endpoint, showing statistically significant improvement in motor aspects of experiences of daily living, adding that it expects results from a Phase 3 study of tavapadon as a flexible-dose monotherapy by the end of the year.
AbbVie said it plans to use full results from the study to support regulatory submissions of tavapadon as a treatment for Parkinson's disease. The company picked up tavapadon as part of its recently completed $8.7 billion acquisition of Cerevel Therapeutics.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 26, 2024 08:40 ET (12:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now